Rituximab add-on therapy for breakthrough relapsing MS: a 52-week phase II trial
Abstract
B cells and the humoral immune system have been implicated in the pathogenesis of multiple sclerosis (MS). This study sought to evaluate the efficacy, safety, and tolerability of add-on therapy with rituximab, a monoclonal antibody that depletes circulating B cells, in subjects with relapsing MS with breakthrough disease defined by clinical and MRI activity (Class III evidence).
METHODS: Thirty subjects with a relapse within the past 18 months despite use of an injectable disease-modifying agent, and with at least 1 gadolinium-enhancing (GdE) lesion on any of 3 pretreatment MRIs, received rituximab administered at 375 mg/m(2) weekly x 4 doses. Three monthly posttreatment brain MRI scans were obtained beginning 12 weeks after the first infusion. Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) were obtained at baseline and throughout the post-treatment follow-up. ... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1394
Rituximab add-on therapy for breakthrough relapsing MS
Rituximab add-on therapy for breakthrough relapsing MS
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 11086 Views
-
Last post by NHE
-
- 0 Replies
- 1035 Views
-
Last post by NHE
-
- 2 Replies
- 1141 Views
-
Last post by David1949
-
- 0 Replies
- 2147 Views
-
Last post by frodo
-
- 2 Replies
- 1610 Views
-
Last post by jimmylegs
-
- 0 Replies
- 1207 Views
-
Last post by NHE
-
- 0 Replies
- 1781 Views
-
Last post by Petr75
-
- 0 Replies
- 10628 Views
-
Last post by NHE
-
- 2 Replies
- 1851 Views
-
Last post by frodo